Among the analyzed laboratory markers available at baseline and after CGRP-mAbs therapy start, baseline lymphopenia demonstrated a statistically significant difference between patients receiving CGRP-mAbs with immunomodulatory treatment (P = 0.049), with higher percentage of Lymphopenia grade 1 among patients with autoimmune diseases, while no statistically significant differences were observed for baseline VSG (P = 0.149), baseline CRP (P = 0.091) and baseline RF was no difference in those with autoimmune disease activation (Table Supplementary 4). This evidence concerns the gene CRP and lymphopenia.